Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. | UCSF Helen Diller Family Comprehensive Cancer Center

Author List

Yamamoto Y, Tsunedomi R, Fujita Y, Otori T, Ohba M, Kawai Y, Hirata H, Matsumoto H, Haginaka J, Suzuki S, Dahiya R, Hamamoto Y, Matsuyama K, Hazama S, Nagano H, Matsuyama H

Publication

Oncotarget

Publication ID (Profile URL)

https://researcherprofiles.org/profile/7236080

Publication Year

2018

PubMed ID

29682213

Publication Title

Yamamoto Y, Tsunedomi R, Fujita Y, Otori T, Ohba M, Kawai Y, Hirata H, Matsumoto H, Haginaka J, Suzuki S, Dahiya R, Hamamoto Y, Matsuyama K, Hazama S, Nagano H, Matsuyama H. Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. Oncotarget. 2018 Mar 30; 9(24):17160-17170.